Celularity Inc.

Contributing Author

Recent Articles by Celularity Inc.

Jun-04	Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies CELU GlobeNewswire
Jun-03	Celularity Releases CEO Letter to Shareholders CELU GlobeNewswire
Jun-03	Celularity Appoints Rick Gonzalez as Chief Commercial Officer CELU GlobeNewswire
May-29	Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU +5.94% CELU GlobeNewswire
May-01	Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation CELU GlobeNewswire
Apr-21	Celularity Announces Closing of Transaction with NexGel CELU GlobeNewswire
Apr-17	Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing CELU GlobeNewswire
Mar-12	Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities CELU GlobeNewswire
Mar-10	Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy CELU +11.20% GlobeNewswire
Feb-10	Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses CELU GlobeNewswire
Dec-26	Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations CELU GlobeNewswire
Dec-22	Celularity Announces Closing of Financing Transactions CELU -8.97% GlobeNewswire
Dec-18	Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision CELU +16.00% CELU GlobeNewswire
Oct-30	Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care CELU GlobeNewswire
Oct-14	Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease CELU +11.27% GlobeNewswire
Sep-03	Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance CELU GlobeNewswire
Aug-22	Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU GlobeNewswire
Aug-18	Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt CELU +19.25% GlobeNewswire
Jul-09	Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law CELU +12.17% GlobeNewswire
Jul-01	Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies CELU GlobeNewswire
Jun-10	Celularity Announces Chief Financial Officer Transition CELU -10.45% CELU GlobeNewswire
Jun-02	Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology CELU +6.16% GlobeNewswire
May-30	Celularity Receives Nasdaq Notice Regarding Form 10-Q CELU -7.46% GlobeNewswire
May-09	Celularity Announces Full Year 2024 Operating and Financial Results CELU GlobeNewswire

Celularity Inc.

Recent Articles by Celularity Inc.

Upgrade your Finviz experience